Patents by Inventor Hossein Salimi-Moosavi
Hossein Salimi-Moosavi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9939447Abstract: Compositions, kits, and methods are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. The compositions can include a first reagent including a cleavage-inducing moiety and a first binding agent for a binding site that includes a post-translational modification of a target polypeptide.Type: GrantFiled: August 14, 2015Date of Patent: April 10, 2018Assignee: Monogram Biosciences, Inc.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
-
Publication number: 20170233467Abstract: The present disclosure provides methods of treating ocular disorders using anti-angiogenic antibodies and pharmaceutical formulations.Type: ApplicationFiled: October 16, 2015Publication date: August 17, 2017Applicant: AMGEN INC.Inventors: Shu-Chen Lu, Murielle M. Veniant-Ellison, Jing Xu, Hossein Salimi-Moosavi, Jonathan Daniel Oliner
-
Publication number: 20160069893Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide.Type: ApplicationFiled: August 14, 2015Publication date: March 10, 2016Applicant: MONOGRAM BIOSCIENCES, INC.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
-
Patent number: 9110075Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification.Type: GrantFiled: October 4, 2011Date of Patent: August 18, 2015Assignee: Monogram Biosciences, Inc.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
-
Patent number: 8198031Abstract: Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.Type: GrantFiled: March 12, 2007Date of Patent: June 12, 2012Assignee: Monogram Biosciences, Inc.Inventors: Po-Ying Chan-Yui, Sharat Singh, Hossein Salimi-Moosavi, Yining Shi, Sailaja Pidaparthi, Rajiv Dua, Ali Mukherjee
-
Publication number: 20120088307Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification.Type: ApplicationFiled: October 4, 2011Publication date: April 12, 2012Applicant: MONOGRAM BIOSCIENCES, INC.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
-
Publication number: 20110275096Abstract: Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.Type: ApplicationFiled: May 9, 2011Publication date: November 10, 2011Inventors: Sean C. Moore, Sharat Singh, Hossein Salimi-Moosavi, Liching Cao, Jeff Sperinde
-
Patent number: 7939267Abstract: Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.Type: GrantFiled: November 3, 2005Date of Patent: May 10, 2011Assignee: Laboratory Corporation of America HoldingsInventors: Sean C. Moore, Sharat Singh, Hossein Salimi-Moosavi, Liching Cao, Jeff Sperinde
-
Publication number: 20100291594Abstract: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment.Type: ApplicationFiled: January 18, 2010Publication date: November 18, 2010Applicant: Laboratory Corporation of America HoldingsInventors: Po-Ying CHAN-HUI, Rajiv Dua, Ali Mukherjee, Sailaja Pidaparthi, Hossein Salimi-Moosavi, Yining Shi, Sharat Singh
-
Patent number: 7771929Abstract: Families of compositions are provided as labels, referred to as eTag reporters for attaching to polymeric compounds and assaying based on release of the eTag reporters from the polymeric compound and separation and detection. For oligonucleotides, the eTag reporters are synthesized at the end of the oligonucleotide by using phosphite or phosphate chemistry, whereby mass-modifying regions, charge-modifying regions and detectable regions are added sequentially to produce the eTag labeled reporters. By using small building blocks and varying their combination large numbers of different eTag reporters can be readily produced attached to a binding compound specific for the target compound of interest for identification. Protocols are used that release the eTag reporter when the target compound is present in the sample.Type: GrantFiled: April 18, 2003Date of Patent: August 10, 2010Assignee: Monogram Biosciences, Inc.Inventors: Sharat Singh, Tracy Matray, Hossein Salimi-Moosavi
-
Patent number: 7648828Abstract: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment.Type: GrantFiled: January 21, 2005Date of Patent: January 19, 2010Assignee: Monogram Biosciences, Inc.Inventors: Po-Ying Chan-Hui, Rajiv Dua, Ali Mukherjee, Sailaja Pidaparthi, Hossein Salimi-Moosavi, Yining Shi, Sharat Singh
-
Publication number: 20090111127Abstract: The invention is directed to a new class of biomarker in patient samples comprising dimers of cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers.Type: ApplicationFiled: October 2, 2007Publication date: April 30, 2009Inventors: Po-Ying Chan-Hui, Rajiv Dua, Ali Mukherjee, Sailaja Pidaparthi, Hossein Salimi-Moosavi, Yining Shi, Sharat Singh
-
Publication number: 20090011432Abstract: Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.Type: ApplicationFiled: July 21, 2008Publication date: January 8, 2009Applicant: Monogram Biosciences, Inc.Inventors: Po-Ying Chan-Hui, Sharat Singh, Hossein Salimi-Moosavi, Hasan Tahir, Gerald J. Wallweber, Hrair Kirakosssian, Tracy J. Matray
-
Publication number: 20080311674Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide.Type: ApplicationFiled: August 10, 2007Publication date: December 18, 2008Applicant: Monogram Biosciences, Inc.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracey J. Matray, Vincent S. Hernandez
-
Publication number: 20080187948Abstract: A method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more heterodimers of ErbB, or Her, cell surface membrane receptors measured directly in a patient sample is described. The invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more heterodimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.Type: ApplicationFiled: December 27, 2007Publication date: August 7, 2008Applicant: Monogram Biosciences Inc.Inventors: Po-Ying Chan-Hui, Rajiv Dua, Ali Mukherjee, Sailaja Pidaparthi, Hossein Salimi-Moosavi, Yining Shi, Sharat Singh
-
Patent number: 7402397Abstract: Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.Type: GrantFiled: August 10, 2004Date of Patent: July 22, 2008Assignee: Monogram BioSciences, Inc.Inventors: Po-Ying Chan-Hui, Sharat Singh, Hossein Salimi-Moosavi, Hasan Tahir, Gerald J. Wallweber, Hrair Kirakosssian, Tracy J. Matray
-
Patent number: 7341362Abstract: A photoactivation apparatus (200) separately delivers light to a plurality of wells of a multiwell plate (110). The device-includes a plurality of light emitting diodes (210) attached to a first surface of a substrate (220) such that when the photoactivation apparatus is positioned on the multiwell plate each of the light emitting diodes delivers light to one corresponding well. The light emitting diodes (210) may extend at least partially into the wells of the multiwell plate. A heat sink (250) and fan may be provided on the device to dissipate heat generated by the light emitting diodes. The components are preferably enclosed in a conveniently-sized housing (270). The housing may include one or more grips and air vents. The apparatus includes an interlocking lip (230) defining a recess which is sized to receive at least a portion of the multiwell plate. A power supply connected to the apparatus and configured to provide an equal voltage across each of the light emitting diodes.Type: GrantFiled: December 18, 2002Date of Patent: March 11, 2008Assignee: Monogram Biosciences, Inc.Inventors: Torleif Bjornson, Hrair Kirakossian, Albert W. Brown, Jr., William Wevers, Hossein Salimi-Moosavi
-
Patent number: 7255999Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide.Type: GrantFiled: May 21, 2002Date of Patent: August 14, 2007Assignee: Monogram Biosciences, Inc.Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
-
Publication number: 20060199231Abstract: Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.Type: ApplicationFiled: November 3, 2005Publication date: September 7, 2006Inventors: Sean Moore, Sharat Singh, Hossein Salimi-Moosavi, Liching Cao, Jeff Sperinde
-
Patent number: RE44437Abstract: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment.Type: GrantFiled: January 18, 2012Date of Patent: August 13, 2013Assignee: Monogram Biosciences, Inc.Inventors: Po-Ying Chan-Hui, Rajiv Dua, Ali Mukherjee, Sailaja Pidaparthi, Hossein Salimi-Moosavi, Yining Shi, Sharat Singh